Development of a Taiwan cancer-related fatigue cognition questionnaire

reliability and validity

Shih-Chiung Lai, Wei-Chun Lin, Chien-Hsin Chen, Szu-Yuan Wu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

PURPOSE: We prospectively designed a Taiwan cancer-related fatigue cognition questionnaire, version 1.0 (TCRFCQ-V1.0), for Taiwanese patients with cancer and investigated the reliability and validity of this questionnaire.

RESULTS: The completion rate of the TCRFCQ-V1.0 was high (97% of the patients completed all items), and the rate of missing data was low (0.2%-1.1% for each item). Moreover, the Cronbach alpha value was 0.889. We eliminated 5 items because their respective Cronbach alpha values were higher than the total mean value of Cronbach's alpha. Overall, the TCRFCQ-V1.0 had adequate Cronbach alpha coefficients (range, from 0.882 to 0.889). In addition, the results of Bartlett's test were significant (chi-squared, 2390.11; p < 0.001), indicating the appropriateness of factor analysis. Sampling adequacy was confirmed by the Kaiser-Meyer-Olkin statistic of 0.868. Through exploratory factor analysis, we identified 6 factors with eigenvalues of > 1, and the scree plot indicated no flattening factors. Overall, 28 items achieved a factor loading of ≥ 0.55.

MATERIALS AND METHODS: We enrolled patients with cancer who were aged > 18 years, had received a pathological diagnosis of cancer, and had undergone cancer treatments such as surgery, chemotherapy, radiotherapy, or concurrent chemoradiotherapy at a single institute in Taiwan. Of the identified 167 eligible patients, 161 (96.4%) were approached. Of these patients, 6 (7.2%) declined to participate and 155 (92.8%) were interviewed. The initial 43 items in the TCRFCQ-V1.0 were assessed for ceiling and floor effects.

CONCLUSIONS: The TCRFCQ-V1.0 is a reliable and valid instrument for measuring CRF cognition in Taiwanese patients with cancer.

Original languageEnglish
JournalOncotarget
DOIs
Publication statusE-pub ahead of print - Mar 16 2017

Fingerprint

Taiwan
Reproducibility of Results
Cognition
Fatigue
Neoplasms
Surveys and Questionnaires
Chemoradiotherapy
Radiotherapy
Drug Therapy

Keywords

  • Journal Article

Cite this

Development of a Taiwan cancer-related fatigue cognition questionnaire : reliability and validity. / Lai, Shih-Chiung; Lin, Wei-Chun; Chen, Chien-Hsin; Wu, Szu-Yuan.

In: Oncotarget, 16.03.2017.

Research output: Contribution to journalArticle

@article{54357adef0624cc69b755af3d1a53503,
title = "Development of a Taiwan cancer-related fatigue cognition questionnaire: reliability and validity",
abstract = "PURPOSE: We prospectively designed a Taiwan cancer-related fatigue cognition questionnaire, version 1.0 (TCRFCQ-V1.0), for Taiwanese patients with cancer and investigated the reliability and validity of this questionnaire.RESULTS: The completion rate of the TCRFCQ-V1.0 was high (97{\%} of the patients completed all items), and the rate of missing data was low (0.2{\%}-1.1{\%} for each item). Moreover, the Cronbach alpha value was 0.889. We eliminated 5 items because their respective Cronbach alpha values were higher than the total mean value of Cronbach's alpha. Overall, the TCRFCQ-V1.0 had adequate Cronbach alpha coefficients (range, from 0.882 to 0.889). In addition, the results of Bartlett's test were significant (chi-squared, 2390.11; p < 0.001), indicating the appropriateness of factor analysis. Sampling adequacy was confirmed by the Kaiser-Meyer-Olkin statistic of 0.868. Through exploratory factor analysis, we identified 6 factors with eigenvalues of > 1, and the scree plot indicated no flattening factors. Overall, 28 items achieved a factor loading of ≥ 0.55.MATERIALS AND METHODS: We enrolled patients with cancer who were aged > 18 years, had received a pathological diagnosis of cancer, and had undergone cancer treatments such as surgery, chemotherapy, radiotherapy, or concurrent chemoradiotherapy at a single institute in Taiwan. Of the identified 167 eligible patients, 161 (96.4{\%}) were approached. Of these patients, 6 (7.2{\%}) declined to participate and 155 (92.8{\%}) were interviewed. The initial 43 items in the TCRFCQ-V1.0 were assessed for ceiling and floor effects.CONCLUSIONS: The TCRFCQ-V1.0 is a reliable and valid instrument for measuring CRF cognition in Taiwanese patients with cancer.",
keywords = "Journal Article",
author = "Shih-Chiung Lai and Wei-Chun Lin and Chien-Hsin Chen and Szu-Yuan Wu",
year = "2017",
month = "3",
day = "16",
doi = "10.18632/oncotarget.16285",
language = "English",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",

}

TY - JOUR

T1 - Development of a Taiwan cancer-related fatigue cognition questionnaire

T2 - reliability and validity

AU - Lai, Shih-Chiung

AU - Lin, Wei-Chun

AU - Chen, Chien-Hsin

AU - Wu, Szu-Yuan

PY - 2017/3/16

Y1 - 2017/3/16

N2 - PURPOSE: We prospectively designed a Taiwan cancer-related fatigue cognition questionnaire, version 1.0 (TCRFCQ-V1.0), for Taiwanese patients with cancer and investigated the reliability and validity of this questionnaire.RESULTS: The completion rate of the TCRFCQ-V1.0 was high (97% of the patients completed all items), and the rate of missing data was low (0.2%-1.1% for each item). Moreover, the Cronbach alpha value was 0.889. We eliminated 5 items because their respective Cronbach alpha values were higher than the total mean value of Cronbach's alpha. Overall, the TCRFCQ-V1.0 had adequate Cronbach alpha coefficients (range, from 0.882 to 0.889). In addition, the results of Bartlett's test were significant (chi-squared, 2390.11; p < 0.001), indicating the appropriateness of factor analysis. Sampling adequacy was confirmed by the Kaiser-Meyer-Olkin statistic of 0.868. Through exploratory factor analysis, we identified 6 factors with eigenvalues of > 1, and the scree plot indicated no flattening factors. Overall, 28 items achieved a factor loading of ≥ 0.55.MATERIALS AND METHODS: We enrolled patients with cancer who were aged > 18 years, had received a pathological diagnosis of cancer, and had undergone cancer treatments such as surgery, chemotherapy, radiotherapy, or concurrent chemoradiotherapy at a single institute in Taiwan. Of the identified 167 eligible patients, 161 (96.4%) were approached. Of these patients, 6 (7.2%) declined to participate and 155 (92.8%) were interviewed. The initial 43 items in the TCRFCQ-V1.0 were assessed for ceiling and floor effects.CONCLUSIONS: The TCRFCQ-V1.0 is a reliable and valid instrument for measuring CRF cognition in Taiwanese patients with cancer.

AB - PURPOSE: We prospectively designed a Taiwan cancer-related fatigue cognition questionnaire, version 1.0 (TCRFCQ-V1.0), for Taiwanese patients with cancer and investigated the reliability and validity of this questionnaire.RESULTS: The completion rate of the TCRFCQ-V1.0 was high (97% of the patients completed all items), and the rate of missing data was low (0.2%-1.1% for each item). Moreover, the Cronbach alpha value was 0.889. We eliminated 5 items because their respective Cronbach alpha values were higher than the total mean value of Cronbach's alpha. Overall, the TCRFCQ-V1.0 had adequate Cronbach alpha coefficients (range, from 0.882 to 0.889). In addition, the results of Bartlett's test were significant (chi-squared, 2390.11; p < 0.001), indicating the appropriateness of factor analysis. Sampling adequacy was confirmed by the Kaiser-Meyer-Olkin statistic of 0.868. Through exploratory factor analysis, we identified 6 factors with eigenvalues of > 1, and the scree plot indicated no flattening factors. Overall, 28 items achieved a factor loading of ≥ 0.55.MATERIALS AND METHODS: We enrolled patients with cancer who were aged > 18 years, had received a pathological diagnosis of cancer, and had undergone cancer treatments such as surgery, chemotherapy, radiotherapy, or concurrent chemoradiotherapy at a single institute in Taiwan. Of the identified 167 eligible patients, 161 (96.4%) were approached. Of these patients, 6 (7.2%) declined to participate and 155 (92.8%) were interviewed. The initial 43 items in the TCRFCQ-V1.0 were assessed for ceiling and floor effects.CONCLUSIONS: The TCRFCQ-V1.0 is a reliable and valid instrument for measuring CRF cognition in Taiwanese patients with cancer.

KW - Journal Article

U2 - 10.18632/oncotarget.16285

DO - 10.18632/oncotarget.16285

M3 - Article

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

ER -